DEB‐TACE vs cTACE for inoperable HCC

Publisher： John Wiley & Sons Inc

E-ISSN： 1872-034x|45|2|190-200

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.45, Iss.2, 2015-01, pp. : 190-200

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC

By Yang Po  

Advances in Therapy, Vol. 25, Iss. 8, 2008-08 ,pp. : 787-794

Springer Publishing Company

Access to resources Recommend Favorite

TACE IN THE ENDOCRINE MANAGEMENT OF PROSTATIC CARCINOMA

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 5, Iss. 4, 1957-04 ,pp. : 453-455

John Wiley & Sons Inc

Access to resources Recommend Favorite

Intermediate stage treatment: Is TACE enough?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. 1, 2018-01 ,pp. : 187-187

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602

By Sato Yozo  

Upsala Journal of Medical Sciences, Vol. 118, Iss. 1, 2013-03 ,pp. : 16-22

Informa Healthcare

Access to resources Recommend Favorite

Response to Intermediate stage treatment: Is TACE enough?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 38, Iss. 1, 2018-01 ,pp. : 188-189

John Wiley & Sons Inc

Access to resources Recommend Favorite